期刊
PEDIATRIC PULMONOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1002/ppul.26824
关键词
aeroallergen sensitization; asthma development; palivizumab; passive smoking; respiratory syncytial virus
This study investigated whether prophylaxis with the anti-RSV monoclonal antibody palivizumab given to preterm infants reduced the incidence of subsequent recurrent wheezing and/or development of asthma. The results showed that at 10 years of age, there was no significant difference in recurrent wheezing or asthma development between the treated and untreated groups. However, there was a significant correlation between maternal passive smoking with aeroallergen sensitization and development of asthma.
BackgroundRespiratory syncytial virus (RSV) causes not only infantile recurrent wheezing but also the development of asthma. To investigate whether palivizumab, an anti-RSV monoclonal antibody, prophylaxis given to preterm infants during the first RSV season reduces the incidence of subsequent recurrent wheezing and/or development of asthma, at 10 years of age.MethodsWe conducted an observational prospective multicenter (52 registered hospitals in Japan) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed for 6 years. During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice (SCELIA study). Here, we followed these subjects until 10 years of age. Parents of study subjects reported the patients' physician's assessment of recurrent wheezing/asthma, using a report card and a novel mobile phone-based reporting system using the internet. The relationship between RSV infection and asthma development, as well as the relationship between other factors and asthma development, were investigated.ResultsOf 154 preterm infants enrolled, 113 received palivizumab during the first year of life. At 10 years, although both recurrent wheezing and development of asthma were not significantly different between the treated and untreated groups, maternal smoking with aeroallergen sensitization of the patients was significantly correlated with physician-diagnosed asthma.ConclusionsIn contrast to the prior study results at 6 years, by 10 years palivizumab prophylaxis had no impact on recurrent wheezing or asthma, but there was a significant correlation between maternal passive smoking with aeroallergen sensitization and development of asthma by 10 years of age.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据